Rosterolone
 | |
| Clinical data | |
|---|---|
| Other names | SH-434; 17α-Propylmesterolone; 17β-Hydroxy-1α-methyl-17α-propyl-5α-androstan-3-one |
| Routes of administration | Topical |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.071.904 |
| Chemical and physical data | |
| Formula | C23H38O2 |
| Molar mass | 346.54662 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rosterolone (INN) (developmental code name SH-434), also known as 17α-propylmesterolone or 1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one, is a steroidal antiandrogen which was first described in 1984 and was developed for topical administration but was never marketed.[1][2][1] It has shown some efficacy in the treatment of acne, and lacks systemic effects with either topical or systemic administration.[3][1][2] Rosterolone is a derivative of mesterolone, which, in contrast, is an androgen and anabolic steroid.
See also
References
- ^ a b c Luderschmidt, Christoph; Eiermann, Wolfgang; Jawny, Johannes; Bidlingmaier, Frank; Ring, Johannes (1984). "17?-Propylmesterolone (SH 434): an antiandrogenic sebosuppressive substance not influencing circulating testosterone concentrations". Naunyn-Schmiedeberg's Archives of Pharmacology. 328 (2): 214–218. doi:10.1007/BF00512076. ISSN 0028-1298.
- ^ a b Singh, Shankar; Gauthier, Sylvain; Labrie, Fernand (2000). "Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships". Current Medicinal Chemistry. 7 (2): 211–247. doi:10.2174/0929867003375371. ISSN 0929-8673. PMID 10637363.
- ^ Neumann, F.; Töpert, M. (1990). "Antiandrogens and Hair Growth: Basic Concepts and Experimental Research": 791–826. doi:10.1007/978-3-642-74612-3_34.
{{cite journal}}: Cite journal requires|journal=(help)
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |